Opendata, web and dolomites

LuMaSense

A Non-Invasive Test for Guiding Follow–up of Patients with CT-Detected Lung Nodules

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 LuMaSense project word cloud

Explore the words cloud of the LuMaSense project. It provides you a very rough idea of what is the project "LuMaSense" about.

worldwide    transform    completing    market    positive    placement    save    false    urgent    costly    specificity    rate    powerful    delay    commercially    96    technological    countries    diag    stages    fund    implication    technique    successful    off    12    transfer    billion    ip    16    conducting    invasive    morbidity    poc    ct    complexity    utilizing    cancer    complementary    cancerous    exists    breath    company    optimal    stand    usefulness    undergone    evaluation    idea    treatment    lung    front    speed    detected    mortality    prototype    translated    relies    ldct    care    operation    rationale    clinical    spin    lc    24    health    noninvasive    unnecessary    device    optimization    portfolio    sensitivity    programs    competitors    nodule    covered    tool    oriented    mature    distinguish    alone    malignant    economic    action    marketable    erc    immediately    healthcare    combination    patients    portability    group    plans    grant    auxiliary    screening    reduce   

Project "LuMaSense" data sheet

The following table provides information about the project.

Coordinator
TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY 

Organization address
address: SENATE BUILDING TECHNION CITY
city: HAIFA
postcode: 32000
website: www.technion.ac.il

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 150˙000 €
 EC max contribution 150˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2014-PoC
 Funding Scheme ERC-POC
 Starting year 2015
 Duration (year-month-day) from 2015-06-01   to  2016-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY IL (HAIFA) coordinator 150˙000.00

Map

 Project objective

This PoC is a commercially-oriented spin-off from our “DIAG-CANCER” ERC project, addressing an urgent clinical need in the field of lung cancer (LC). The rationale behind this PoC is that CT-based LC screening programs are emerging in many countries worldwide. However, the high false positive rate of this technique (96% out of the 24% positive CT findings are non-cancerous) has been a major challenge in front those plans. This is because the CT-detected non-cancerous group has undergone unnecessary invasive procedures that are both costly and associated with significant morbidity and mortality. With this PoC project, we aim to increase the specificity of the LDCT based screening program by utilizing an auxiliary noninvasive breath test to distinguish between malignant and non-cancerous CT findings. The proposed breath test relies on a novel stand-alone device that provide an improved combination of speed, sensitivity, portability, low complexity, easy operation and low production cost. In order to transform our idea and current technology into a marketable device we propose taking several steps: (i) optimization of a prototype device and evaluation of its clinical usefulness through clinical studies; (ii) completing the IP portfolio of the device; and (iii) conducting detailed market research to identify the optimal placement in the healthcare market and possible competitors. After completing these stages, to be covered by the present grant, we propose to proceed to the technology transfer to a mature health care company or through complementary fund to advance the technological plans. If successful, the proposed PoC can be translated immediately into a powerful tool for the management of nodule-positive patients. It will both reduce the rate of unnecessary invasive procedures, and on the other hand, will avoid treatment delay when cancer exists. The economic implication of this action is a significant save of ~$12-16 billion for the healthcare system worldwide.

 Publications

year authors and title journal last update
List of publications.
2016 Inbar Nardi-Agmon, Manal Abud-Hawa, Ori Liran, Naomi Gai-Mor, Maya Ilouze, Amir Onn, Jair Bar, Dekel Shlomi, Hossam Haick, Nir Peled
Exhaled Breath Analysis for Monitoring Response to Treatment in Advanced Lung Cancer
published pages: 827-837, ISSN: 1556-0864, DOI: 10.1016/j.jtho.2016.02.017
Journal of Thoracic Oncology 11/6 2019-07-22

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LUMASENSE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LUMASENSE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

PROGRESS (2019)

The Enemy of the Good: Towards a Theory of Moral Progress

Read More  

HOLI (2019)

Deep Learning for Holistic Inference

Read More  

DISINTEGRATION (2019)

The Mass Politics of Disintegration

Read More